{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:45:43Z","timestamp":1780116343337,"version":"3.54.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s10620-018-5326-7","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T09:18:54Z","timestamp":1539681534000},"page":"698-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA"],"prefix":"10.1007","volume":"64","author":[{"given":"Alexander L.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesuk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Sheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoona A.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,16]]},"reference":[{"key":"5326_CR1","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.cgh.2015.08.015","volume":"13","author":"P Udompap","year":"2015","unstructured":"Udompap P, Kim D, Kim WR. Current and future burden of chronic nonmalignant liver disease. Clin Gastroenterol Hepatol. 2015;13:2031\u20132041.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"5326_CR2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","volume":"53","author":"V Ratziu","year":"2010","unstructured":"Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD\/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372\u2013384.","journal-title":"J Hepatol."},{"key":"5326_CR3","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005\u20132023.","journal-title":"Hepatology."},{"key":"5326_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology."},{"key":"5326_CR5","doi-asserted-by":"publisher","first-page":"e0173499","DOI":"10.1371\/journal.pone.0173499","volume":"12","author":"M Le","year":"2017","unstructured":"Le M, Devaki P, Te H, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017;12:e0173499.","journal-title":"PLoS One."},{"key":"5326_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"5326_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/jhep.2002.34734","volume":"36","author":"WR Kim","year":"2002","unstructured":"Kim WR, Brown RS, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227\u2013242.","journal-title":"Hepatology."},{"key":"5326_CR8","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/lt.24507","volume":"22","author":"K Young","year":"2016","unstructured":"Young K, Aguilar M, Gish R, et al. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. Liver Transpl. 2016;22:1356\u20131366.","journal-title":"Liver Transpl."},{"key":"5326_CR9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/MPG.0b013e318192d224","volume":"48","author":"C Koebnick","year":"2009","unstructured":"Koebnick C, Getahun D, Reynolds K, et al. Trends in nonalcoholic fatty liver disease-related hospitalizations in US children, adolescents, and young adults. J Pediatr Gastroenterol Nutr. 2009;48:597\u2013603.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"5326_CR10","unstructured":"Patient Discharge Data File Documentation. In: SAS Version 9.2 ed: Office of Statewide Health Planning & Development; 2011."},{"key":"5326_CR11","unstructured":"Goldman L, Chu P, Prothro C, et al. Accuracy of Condition Present on Admission, do not Resuscitate, and e-Codes in California Patient Discharge Data. University of California, San Francisco Study Consultants Team; 2011."},{"key":"5326_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/MCG.0000000000000071","volume":"49","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Zheng L, Stepanova M, et al. Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease. J Clin Gastroenterol. 2015;49:222\u2013227.","journal-title":"J Clin Gastroenterol."},{"key":"5326_CR13","unstructured":"Patient Discharge Pivot Profiles, Office of Statewide Health Planning and Development; Accessed 2017. \n                    https:\/\/www.oshpd.ca.gov\/HID\/IP-Discharges-Pivot.html\n                    \n                  ."},{"key":"5326_CR14","volume-title":"Statistical Brief #225","author":"K Mcdermott","year":"2017","unstructured":"Mcdermott K. Trends in hospital inpatient stays in the United States, 2005\u20132014. In: Elixhauser A, ed. Statistical Brief #225. Rockville, MD: Agency for Healthcare Research and Quality; 2017."},{"key":"5326_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imj.12624","volume":"45","author":"JC Hsiang","year":"2015","unstructured":"Hsiang JC, Bai WW, Raos Z, et al. Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand. Intern Med J. 2015;45:160\u2013169.","journal-title":"Intern Med J."},{"key":"5326_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123\u2013133.","journal-title":"Hepatology."},{"key":"5326_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","volume":"79","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Zaza G, Byrne CD, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism. 2018;79:64\u201376.","journal-title":"Metabolism."},{"key":"5326_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.molmed.2015.08.005","volume":"21","author":"G Musso","year":"2015","unstructured":"Musso G, Cassader M, Cohney S, et al. Emerging liver-kidney interactions in nonalcoholic fatty liver disease. Trends Mol Med. 2015;21:645\u2013662.","journal-title":"Trends Mol Med."},{"key":"5326_CR19","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1007\/s10620-017-4684-x","volume":"62","author":"G Cholankeril","year":"2017","unstructured":"Cholankeril G, Wong RJ, Hu M, et al. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci. 2017;62:2915\u20132922. \n                    https:\/\/doi.org\/10.1007\/s10620-017-4684-x","journal-title":"Dig Dis Sci."},{"key":"5326_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/aje\/kws448","volume":"178","author":"M Lazo","year":"2013","unstructured":"Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: The Third National Health and Nutrition Examination Survey, 1988\u20131994. Am J Epidemiol. 2013;178:38\u201345.","journal-title":"Am J Epidemiol."},{"key":"5326_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u2013357.","journal-title":"Hepatology."},{"key":"5326_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jhep.2018.06.025","volume":"69","author":"SE Mahady","year":"2018","unstructured":"Mahady SE, George J. Predicting the future burden of NAFLD and NASH. J Hepatol. 2018;69:774\u2013775.","journal-title":"J Hepatol."},{"key":"5326_CR23","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/liv.13613","volume":"38","author":"T Jun","year":"2018","unstructured":"Jun T, Yeh M, Yang J, et al. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Int. 2018;38:895\u2013902.","journal-title":"Liver Int."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5326-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5326-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5326-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T23:09:59Z","timestamp":1571180999000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5326-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,16]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["5326"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5326-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,16]]},"assertion":[{"value":"17 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Haesuk Park: Research grants, Gilead, Proteus Digital Health. Yoona Kim: Consultant for Proteus Digital Health. Stocks: Gilead. Mindie Nguyen: Research grants, Gilead, Pfizer. Advisory board\/Consultant, Gilead, Intercept. Alexander L. Nguyen, Pauline Nguyen, and Edward Sheen declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}